Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.54 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.53 |
| ▸ | JAK3 | P52333 | 2/20 | 0.53 |
| ▸ | BTK | Q06187 | 8/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | ITK | Q08881 | 1/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.48 |
| ▸ | TGM2 | P21980 | 1/20 | 0.48 |
| ▸ | CTSC | P53634 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12262344 | 0.93 | EGFR (0.57) | EGFRMAP2K7JAK3BTKKCNH2 | |
| SCHEMBL692807 | 0.89 | EGFR (0.68) | EGFRMAP2K7JAK3BTKKCNH2 | |
| SCHEMBL12262368 | 0.89 | JAK3 (0.64) | EGFRJAK3BTKITKTGM2 | |
| SCHEMBL12262347 | 0.86 | MAP2K7 (0.57) | EGFRMAP2K7JAK3BTKKCNH2 | |
| SCHEMBL691113 | 0.84 | EGFR (0.67) | EGFRMAP2K7JAK3BTKKCNH2 | |
| SCHEMBL690318 | 0.81 | TGM2 (0.71) | EGFRMAP2K7JAK3BTKKCNH2 | |
| SCHEMBL691982 | 0.80 | MTNR1A (0.51) | EGFRJAK3BTKERBB2 | |
| SCHEMBL690536 | 0.80 | MAP2K7 (0.69) | EGFRMAP2K7JAK3BTKKCNH2 | |
| SCHEMBL14769570 | 0.79 | EGFR (0.54) | EGFRJAK3ITKERBB2 | |
| SCHEMBL690191 | 0.78 | MAP2K7 (0.60) | EGFRMAP2K7ITKERBB2CTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296704-B2 | Substituted pyrimidines as protein kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296704-B2 | Substituted pyrimidines as protein kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20140303165-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. | 2014-10-09 | — | — | US | disclosed |
| US-20140303165-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. | 2014-10-09 | — | — | US | disclosed |
| US-20130217688-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130217688-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20110230494-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110230494-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217688-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | EGFR 1981/4885MAP2K7 4438/4885JAK3 439/4885 |
| US-20140303165-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | EGFR 1981/4885MAP2K7 4438/4885JAK3 439/4885 |
| US-20110230494-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | EGFR 1981/4885MAP2K7 4438/4885JAK3 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.